Immunotherapeutic intervention against sarcomas

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 350-356

  Pedrazzoli, Paolo ^a,c   Secondino, Simona ^a   Perfetti, Vittorio ^a   Comoli, Patrizia ^a   Montagna, Daniela ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO)   (Italy)

Author keywords

Immunotherapy; Sarcoma

Indexed keywords

CANCER VACCINE; CISPLATIN; DENDRITIC CELL VACCINE; DOXORUBICIN; IFOSFAMIDE; INTERLEUKIN 2; METHOTREXATE; PEGINTERFERON ALPHA2B;

ADOPTIVE T LYMPHOCYTE THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL THERAPY; DRUG MEGADOSE; EFFECTOR CELL; EWING SARCOMA; HUMAN; IMMUNOMODULATION; NONSPECIFIC IMMUNOMODULATION; OSTEOSARCOMA; REVIEW; SARCOMA; TUMOR INFILTRATING THERAPY;

EID: 84875713143     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.350     Document Type: Review

References (75)

1. DeVita VT, Lawrence TS, Rosenberg SA. Cancer: Principles and Practice of Oncology - 8th edition. US: Lippincott Williams & Wilkins, 2008.
2. Maki RG. Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Current Opinion in Oncology. 2001;13:270-4.
3. Pollack SM., Loggers ET, Rodler ET, Yee C, Jones RL. Immune-based therapies for sarcoma. Sarcoma. 2011;2011:438940.
4. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Annals of Surgery. 1989;210:474-85.
5. Schwinger W, Klass V, Benesch M, et al. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Annals of Oncology. 2005;16:1199-06.
6. Murray JL, Kleinerman ES, Cunningham JE, et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Journal of Clinical Oncology. 1989;7:1915-25.
7. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. Journal of Clinical Oncology. 1992;10:1310-16.
8. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of Clinical Oncology. 2005;23:2004-11.
9. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009;115:5339-48.
10. Ito H, Murakami K, Yanagawa T. Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma. Case reports. Cancer. 1980;46:1562-65.
11. Edmonson JH, Long HJ, Frytak S, Smithson WA, Itri LM. Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas. Cancer Treatment Reports. 1987;71:747-8.
12. Winkler K, Beron G, Kotz R. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. Journal of Clinical Oncology. 1984;2:617-24.
13. Steger GG, Wrba F, Mader R, Schlappack O, Dittrich C, Rainer H. Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses. European Journal of Cancer. 1991;27:254-6.
14. Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncologica. 1995;34:877-80.
15. Müller CR, Smeland S, Bauer HCF, Sæter G, Strander H. Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncologica. 2005;44:475-80.
16. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine. 2010;363:411-22.
17. Dillman R, Barth N, Selvan S, et al. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biotherapy and Radiopharmaceuticals. 2004;19:581-88.
18. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Research. 2001;61:8513-19.
19. Mackall CL, Rhee EH, Read EJ, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clinical Cancer Research. 2008;14:4850-8.
20. Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Medical and Pediatric Oncology. 2002;38:158-64.
21. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Hara T. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatric Transplantation. 2009;13:746-53.
22. Ullenhag GJ, Spendlove I, Watson NFS, Kallmeyer C, Pritchard-Jones K, Durrant LG. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clinical Immunology. 2008;128:148-54.
23. Pritchard-Jones K, Spendlove I, Wilton C, et al. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. British Journal of Cancer. 2005;92:1358-65.
24. Kawaguchi S, Wada T, Ida K, et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. Journal of Translational Medicine. 2005;3:1.
25. Ida K, Kawaguchi S, Sato Y, et al. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. Journal of Immunology. 2004;173:1436-43.
26. Zhang S, Cordon-Cardo C, Zhang HS, et al. Selection of tumor antigens as targets for immune attack using immunohisto-chemistry: I. Focus on gangliosides. International Journal of Cancer. 1997;73:42-9.
27. Heiner JP, Miraldi F, Kallick S, et al. Localization of G(D2)-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Research. 1987;47:5377-81.
28. Lipinski M, Braham K, Philip I. Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Research. 1987;47:183-7.
29. Perez CA, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer Journal. 2002;8:384-94.
30. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of inter-group trial E1694/S9512/C509801. J Clini Oncol. 2001;19:2370-80.
31. Moscovitch, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol 1984;132:997-1000.
32. Deichman GI, Kashkina LM, Kluchareva TE, Vendrov EL, Matveeva VA. Inhibition of experimental and spontaneous lung metastases of highly metastatic Syrian hamster sarcoma cells by non-activated bone marrow and peritoneal exudate cells. Int J Cancer 1983;3:609-15.
33. Castagna L, Sarina B, Todisco E, Mazza R, Santoro A. Lack of activity of allogeneic stem cell transplantation with reduced-intensity conditioning regimens in advanced sarcomas. Bone Marrow Transplant 2005;35:421-2.
34. Misawa A, Hosoi H, Tsuchiya K, Iehara T, Sawada T, Sugimoto T. Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. Pediatr Hematol Oncol 2003;20:151-5.
35. Secondino S, Carrabba MG, Pedrazzoli P, et al. Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. Haematologica. 2007;92:418-20.
36. Thiel U, Wawer A, Wolf P, et al. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol. 2011; Epub ahead of print.
37. Demirer T, Barkholt L, Blaise D, et al., on behalf of the EBMT Solid Tumors Working Party. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clin Pract Oncol 2008;5:256-67.
38. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-41.
39. Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984;159:495-507.
40. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 1985;45:3735-41.
41. Berezhnaya NM, Vinnichuk YD, Belova OB. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin. Exp Oncol. 2008;30:52-5.
42. Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 1987;316:889-97.
43. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
44. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010;2010:435745.
45. Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol. 2003;77:175-9.
46. Wang Y, Dai H, Li H, Lv H, Wang T, Fu X, et al. Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells. Clin Dev Immunol 2011; epub.
47. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IGH. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137:305-10.
48. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001;97:2923-31.
49. Kuçi S, Rettinger E, Voß B, Weber G, Stais M, Kreyenberg H, et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010;95:1579-86.
50. Introna M, Pievani A, Borleri G, Capelli C, Algarotti A, Micò C, et al. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant 2010;16:1603-7.
51. Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 2009;9:831-40.
52. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-40.
53. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. Journal of Immunological Methods. 1987;102:127-41.
54. Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Archives of Surgery. 1990;125:200-5.
55. Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T, et al. Activation of autologous or HLA identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extract. Oncol Rep 1999;6:1057-63.
56. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside T. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60:3542-9.
57. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor specific cytotoxic lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001;91:749-756.
58. Montagna D, Schiavo R, Gibelli N, et al. Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. Int J Cancer 2004;110:76-86.
59. Montagna D, Turin I, Schiavo R, et al. Feasibility and safety of adoptive immunotherapy with ex-vivo generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy. 2011; in press.
60. Kano M, Tsukahara T, Emori M, et al. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma. Cancer Sci. 2011; Epub ahead of print.
61. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105:1898-904.
62. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous EBV-targeted cytotoxic T-lymphocytes. J Clin Oncol 2005;23:8942-9.
63. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009;113:2442-50.
64. Secondino S, Zecca M, Licitra L, et al. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol 2011; in press.
65. Okroj M, Tedeschi R, Mancuso R. Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters. Vaccine. 2011;29:1129-34.
66. McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med. 1995;332:12-8.
67. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nature Reviews Cancer 2003;3:35-45.
68. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Medicine 2003; 9: 279-86.
69. Kershaw MH, Westwood JA, Parker LL Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene modified T cells for ovarian cancer. Clinical Cancer Research 2006;12:6106-15.
70. Lamers CH, Langeveld SC, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunology Immunotherapy 2007;56:1875-83.
71. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70.
72. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703.
73. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-24.
74. Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94:1914-8.
75. Gure AO, Chua R, Williamson B, et al: Cancer testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11:8055-62.